Idiopathic Pulmonary Fibrosis (IPF) is a severe parenchymal lung disease characterized by an intense deposition of collagen in the interstitial spaces. The introduction of anti-fibrotic drugs increased patients’ life expectancy highlighting the role of comorbidities in patients’ management and prognosis. IPF is frequently associated with other diseases mainly because of its onset during middle age and sometimes because of the presence of common pathogenic pathways such as in the case of lung cancer. Comorbidities may differently influence prognosis of IPF patients. However, except for major impacting ones as LC, PH and cardiovascular diseases, data exploring their impact on prognosis are still few and sometimes conflicting highlighting the need of new large and targeted studies. In this review we discuss the current knowledge on the most common comorbidities associated with IPF (cardiovascular diseases, pulmonary hypertension, lung cancer, emphysema, gastro-oesophageal reflux and depression), focusing on their prognostic role.
|Titolo:||Comorbidities of IPF: How do they impact on prognosis|
|Data di pubblicazione:||2018|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|Comorbidities-of-IPF-How-do-they-impact-on-prognosis2018Pulmonary-Pharmacology-and-Therapeutics.pdf||Versione Editoriale (PDF)||Administrator|